Filing Summary
Entity identification: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-Q, not a Neurogene Inc. filing. It covers the quarter ended June 30, 2017 and was signed August 8, 2017. Financial amounts are in U.S. dollars unless stated otherwise.
Business Context and Reporting Period
Aquinox was a clinical-stage pharmaceutical company developing rosiptor (formerly AQX-1125), an oral SHIP1 activator, primarily for interstitial cystitis/bladder pain syndrome (IC/BPS). The company had no revenue and no approved products. It reported that rosiptor’s first Phase 3 IC/BPS trial, Leadership 301, was underway; the trial was designed to evaluate 100 mg and 200 mg once-daily doses against placebo.
Financial Performance and Position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $10.5m | $9.2m | $16.3m | $14.1m |
| General and administrative expense | $3.5m | $1.8m | $6.3m | $3.8m |
| Net loss | $13.8m | $10.9m | $22.1m | $17.6m |
| Net loss per share, basic and diluted | $0.59 | $0.63 | $0.94 | $1.02 |
At June 30, 2017, cash and cash equivalents were $27.1m, short-term investments were $104.1m, and long-term investments were zero, versus $32.3m, $70.8m, and $50.0m, respectively, at December 31, 2016. Cash, cash equivalents, and short-term investments totaled $131.3m; working capital was $124.1m. Total liabilities were $8.7m, including $8.1m current liabilities and $0.04m in capital lease obligations. The filing reports no material change in contractual commitments.
For the first half, operating cash use was $21.6m, compared with $13.8m in 2016. Investing activities provided $16.0m, primarily reflecting investment maturities; financing activities provided $0.4m, primarily from option exercises. Cash and cash equivalents fell by $5.2m to $27.1m. The filing reports no gross margin because there was no revenue. No profitability or operating margin was reported.
Material Changes Versus Prior Comparable Period
- First-half net loss increased by $4.5m year over year, while loss per share narrowed to $0.94 from $1.02, reflecting a higher weighted-average share count.
- First-half R&D expense rose $2.1m, which management attributed mainly to increased clinical activity in Leadership 301. G&A expense rose $2.5m, primarily due to higher personnel costs and pre-commercial and market-assessment work.
- First-half operating cash use increased $7.8m year over year. Management cited higher operating expenses and timing of payments for prior-period expenditures.
- Investment allocation shifted toward short-term holdings: long-term investments declined from $50.0m at year-end to zero, while short-term investments increased from $70.8m to $104.1m.
- Stock-based compensation expense was $1.7m for the first half versus $0.9m in 2016. Outstanding options increased to 2.06m from 1.38m at year-end 2016.
Outlook, Commentary, and Risks
- Management expected significant expenses and operating losses to continue and projected R&D spending would rise as rosiptor development advanced. It said existing capital resources were expected to fund operations for at least the next 12 months, while anticipating a need for substantial future financing.
- Leadership 301 was expected to enroll at least 300 female patients and up to 600 patients including males, with 12 weeks of dosing and a 52-week extension. Management said trial results and regulatory discussions would help determine the design and number of further studies needed.
- Key risks include clinical-trial execution and enrollment, uncertain efficacy and safety, regulatory approval, the unvalidated SHIP1 target, dependence on third-party manufacturers and CROs, and the possibility that additional financing may be unavailable or dilutive.
- The filing notes earlier mixed clinical results: the Phase 2 Leadership 201 IC/BPS trial did not achieve statistical significance on its primary endpoint, although it showed a positive trend and statistically significant secondary endpoints. Phase 2 trials in COPD and atopic dermatitis failed to demonstrate efficacy. Animal studies also found gastrointestinal ulcerations in dogs and ocular-lens effects; clinical tolerability had generally been favorable, with gastrointestinal upset the most common reported side effect.
- Interest-rate sensitivity: management estimated that a hypothetical 100-basis-point rate increase would reduce investment fair value by $0.5m. The company did not hedge its foreign-currency exposure. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm the filing entity: the document is Aquinox Pharmaceuticals, Inc., despite the request metadata naming Neurogene Inc.
- Check Leadership 301 enrollment, timelines, dose selection, and subsequent clinical and regulatory updates; the filing provides no clinical results from this Phase 3 trial.
- Assess the adequacy of the stated cash runway against clinical spending and the company’s expected need for future financing.
- Review the filing’s operating-expense table discrepancy: the financial statements report Q2 2017 total operating expenses of $13.995m, while the MD&A table prints $13.955m; the component expenses sum to $13.995m.
- Evaluate the clinical and commercial implications of prior trial outcomes, potential safety findings, and rosiptor’s unvalidated biological target.